

Supplemental Figures





Figure S1: Analysis of the number of neutrophils upon antibody treatment (related to Figure 1). (a-e): FACS dot plots showing representative blood samples at day 28 after the start of the experiment for (a) PBS injected control mice, (b) 50 μ g rat-Ly-6G injected mice, (c) 25 μ g mouse-Ly-6G injected mice, and (d) 100 μ g mouse-Ly-6G injected mice. (e) Zoom in of the longitudinal analysis of the number of CD45⁺ Siglec-F⁺ CD115⁺ SSC^{high} Gr-1⁺ CD11b⁺ neutrophils per 5000 beads in the peripheral blood (n=4 mice per subgroup) of 100 μ g mouse-Ly-6G treated mice, as depicted in Figure 1e.






Figure S2: Gating strategy to retrieve the number of neutrophils per 5000 beads (related to Figure 2). (a-d): FACS dot plots showing representative blood samples at the day before the start of the experiment (day -1) and at the end of the experiment (day 27) for (a) C57Bl6/J, (b) Balb/c, (c) NXG, and (d) SCID mice, injected with 100 μ g mouse-Ly-6G. (e) Zoom in of the longitudinal analysis of the number of CD45⁺ Siglec-F⁺ CD115⁺ SSC^{high} Gr-1⁺ CD11b⁺ neutrophils per 5000 beads in the peripheral blood (n=5 mice per group) of 100 μ g mouse-Ly-6G treated mice, as depicted in Figure 2b.




Figure S3: Number of monocytes, eosinophils, T-, B-, and NK-cells upon Ly6g treatment (related to Figure 1). Flow cytometry analysis of the number of leukocytes in the peripheral blood at day 28 after the start of the experiment (n=8 mice per group, as shown in Figure 1) per 5000 latex beads, showing (a): a significant increase in both Ly-6C⁺ and Ly-6C⁻ CD115⁺ monocytes, but not eosinophils, upon neutrophil depletion with 100 µg mouse-Ly-6G antibody, and (b): no differences in CD3⁺ T-cells, B220⁺ B-cells and NK1.1⁺ NK-cells. Statistics: two-way ANOVA with Bonferroni correction, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.